SMSPHARMA Overzicht aandelen
SMS Pharmaceuticals Limited produceert en verkoopt actieve farmaceutische ingrediënten (API's) en tussenproducten in India en daarbuiten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 3/6 |
SMS Pharmaceuticals Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹241.15 |
| 52 Week Hoogtepunt | ₹398.00 |
| 52 Week Laag | ₹113.30 |
| Bèta | 1.29 |
| 11 maand verandering | -19.68% |
| 3 maanden verandering | -32.43% |
| 1 Jaar Verandering | 96.78% |
| 33 jaar verandering | 85.07% |
| 5 jaar verandering | 507.43% |
| Verandering sinds IPO | 571.26% |
Recent nieuws en updates
Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Rendement voor aandeelhouders
| SMSPHARMA | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | -8.4% | -0.5% | -1.2% |
| 1Y | 96.8% | 41.6% | 25.5% |
Rendement versus industrie: SMSPHARMA overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 41.6 % opleverde.
Rendement versus markt: SMSPHARMA overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 25.5 %.
Prijsvolatiliteit
| SMSPHARMA volatility | |
|---|---|
| SMSPHARMA Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: De aandelenkoers van SMSPHARMA is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van SMSPHARMA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Indian.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1987 | 1,197 | Ramesh Potluri | smspharma.com |
SMS Pharmaceuticals Limited produceert en verkoopt actieve farmaceutische ingrediënten (API's) en tussenproducten in India en daarbuiten. Het bedrijf biedt anti-retrovirale, anti-inflammatoire, anti-virale, anti-diabetische, anti-schimmel, anti-epileptische, anti-migraine, anti-coagulant, anti-psychotische, anti-aginale en anti-ulcerale producten. Het bedrijf is ook betrokken bij contractonderzoek naar peptiden.
SMS Pharmaceuticals Limited Samenvatting
| SMSPHARMA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹20.41b |
| Inkomsten(TTM) | ₹593.38m |
| Inkomsten(TTM) | ₹7.68b |
34.4x
Koers/Winstverhouding2.7x
P/S-verhoudingIs SMSPHARMA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SMSPHARMA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹7.68b |
| Kosten van inkomsten | ₹5.38b |
| Brutowinst | ₹2.31b |
| Overige uitgaven | ₹1.71b |
| Inkomsten | ₹593.38m |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 7.01 |
| Brutomarge | 30.02% |
| Nettowinstmarge | 7.72% |
| Schuld/Eigen Vermogen Verhouding | 50.6% |
Hoe presteerde SMSPHARMA op de lange termijn?
Bekijk historische prestaties en vergelijking